Related Experiment Videos
The British Cardiovascular Society and clinical studies in ischaemic heart disease: from RITA to ORBITA, and beyond
Rasha Al-Lamee1, Louise Aubiniere-Robb2, Colin Berry2,3
1Cardiology, Imperial College Healthcare NHS Trust, London, UK rasha.al-lamee@nhs.net.
Insights
The British Cardiovascular Society (BCS) has significantly influenced ischaemic heart disease (IHD) clinical trials, research, and patient care. This review covers BCS contributions to IHD diagnosis, treatment, and future research directions.
Area of Science:
- Cardiology
- Clinical Trials
- Health Policy
Background:
- The British Cardiovascular Society (BCS) has a long history of involvement in cardiovascular research.
- Ischaemic heart disease (IHD) remains a major global health concern, necessitating robust clinical trials for effective management.
- Understanding the BCS's role provides insight into the evolution of IHD research and clinical practice.
Purpose of the Study:
- To provide a historical overview of the British Cardiovascular Society's (BCS) influence on ischaemic heart disease (IHD) clinical trials.
- To highlight key research, developments, and publications related to IHD supported by the BCS.
- To discuss future perspectives and the evolving landscape of IHD management, including microvascular disease and myocardial infarction with no obstructive coronary arteries.
Main Methods:
- Historical review of BCS activities and influence in IHD clinical trials.
- Analysis of key research, notable publications, and significant developments.
- Discussion of BCS's role in supporting specific trials, such as the RITA trials.
Main Results:
- The BCS has played a pivotal role in shaping IHD clinical trials, from diagnosis to treatment and management.
- Significant advancements in understanding and managing angina, microvascular disease, and myocardial infarction with no obstructive coronary arteries have been influenced by BCS initiatives.
- The BCS has fostered relationships with stakeholders and promoted patient and public involvement in IHD research.
Conclusions:
- The BCS has been instrumental in advancing IHD research and improving patient outcomes through its involvement in clinical trials.
- Future research should continue to address emerging areas like microvascular dysfunction and non-obstructive coronary artery disease.
- Continued collaboration and patient engagement are crucial for future progress in IHD management.
Abstract:
In this article, we provide a historical view of key aspects of British Cardiovascular Society (BCS) influence in clinical trials of ischaemic heart disease (IHD) followed by key research and developments, notable publications and future perspectives. We discuss the role of the BCS and its members. The scope of this article covers clinical trials in stable IHD and acute coronary syndromes, including interventions relating to diagnosis, treatment and management. We discuss the role of the BCS in supporting the original RITA trials. We highlight the changing face of angina and its management providing contemporary and future insights into microvascular disease, ischaemic symptoms with no obstructive coronary arteries and, relatedly, myocardial infarction with no obstructive coronary arteries. The article is presented as a brief overview of the BCS in IHD research, relationships with stakeholders, patient and public involvement and clinical trials from the perspective of past, present and future possibilities.